팜젠사이언스

004720KOSPI의약품 제조업

44.7 / 100

Reference Date: 2026-04-13

Financial Score14.5 / 40

News Sentiment14.2 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Slightly down 1.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Palmgen Science operates in pharmaceuticals, healthcare, and real estate leasing, achieving 16.54 billion KRW in pharmaceutical sales and 650 million KRW in healthcare sales in 2025. Key products include Esomax (for digestive disorders), Bardifin (hypertension treatment), and Kvasitin (hyperlipidemia treatment), with the company enhancing competitiveness through new drug development and quality improvements.

Number of Employees

229people

Average Salary

71.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.804.0Point

PBR

0.56Industry Average 1.045.5Point

Lower than industry avg (good)

ROE

-58.95Industry Average 4.420.0Point

Well below industry avg

Debt Ratio

10.55Industry Average 11.984.0Point

In line with industry avg

Trend 2023~20251.0 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲1.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.4% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 2Neutral 3Negative 0Average Sentiment Score 58

Neutral
최영호 엑세스바이오 회장 "미국에 메드스파 연다…팬데믹 수준으로 ...
엑세스바이오가 코로나19 팬데믹 당시 비축한 현금을 바탕으로 뷰티 방면 M&A에 적극적인 행보를 보이고 있다는 내용이며, 팜이데일리 프리미엄 콘텐츠로 선공개되었다는 언급이 있습니다.
Positive
[주총 포커스] 팜젠사이언스, RCPS 도입…R&D비 조달 경로 확대
팜젠사이언스가 정관 변경을 통해 RCPS 발행 근거를 마련하여 R&D 자금 조달 경로를 확대하고 사업구조 전환을 모색합니다.
Neutral
[바이오스냅] 차헬스케어, '소요한남 레지던스' 헬스케어 서비스 구축
차헬스케어가 '소요한남 레지던스'에 헬스케어 서비스 플랫폼을 구축한다는 소식과 팜젠사이언스의 구강 유산균 출시 소식이 함께 보도되었습니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 3,755Won52-week high 4,92552-week low 3,500

1-month return3.0Point

1m -1.57% (flat)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
Neutral대표이사(대표집행임원)변경(안내공시)2026-03-31
Neutral정기주주총회결과2026-03-31
Neutral[기재정정]의결권대리행사권유참고서류2026-03-23
Neutral감사보고서제출2026-03-23